Skip to contentA
Arcutis Biotherapeutics, Inc.
A
ARQTArcutis Biotherapeutics, Inc. Q3 2022 · 10-Q
Revenue$725.00K$725.00K— vs Q3 2021 Net Income-$107.71M-$107.71MN/M vs Q3 2021 EPS Diluted-$1.89-$1.89N/M vs Q3 2021 Operating Income-$104,748,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Arcutis Biotherapeutics, Inc. · CIK 1787306 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$67,701,000N/M Margins · derivedOperating margin-14448.0%
Net margin-14856.4%
ended Sep 30, 2022 · filed Nov 8, 2022 · 39 d after period end